Vinorelbine Tartrate (Vinorelbine Tartrate)
Overview of Vinorelbine Tartrate
Vinorelbine (Tartrate) is a semi-synthetic, intravenous antineoplastic (anticancer) agent, belongs to the class of vinca alkaloids. Vinorelbine (Tartrate) is a derivative of vinblastine and has structural modifications distinctly different from other vinca alkaloids. The spectrum of activity of vinorelbine is similar to either vincristine or vinblastine, however, vinorelbine may have less neurotoxicity than vincristine. Vinorelbine was approved by the FDA for treatment of advanced non-small cell lung cancer (NSCLC) December 22, 1994. its activity in breast cancer is notable but still requires further investigation. Vinorelbine (Tartrate) is used alone or in combination with other anticancer drugs in the treatment of certain cancers such as lung cancer, breast cancer, ovarian cancer.
Indication of Vinorelbine Tartrate
Vinorelbine Tartrate is primarily indicated in conditions like Lung cancer, and can also be given in adjunctive therapy as an alternative drug of choice in Advanced breast cancer.
Contraindication of Vinorelbine Tartrate
Vinorelbine (Tartrate) is contraindicated in conditions like Bacterial infections,Bone marrow depression.
Side Effects of Vinorelbine Tartrate
The severe or irreversible adverse effects of Vinorelbine (Tartrate), which give rise to further complications include Bone marrow depression.
Precautions of Vinorelbine Tartrate
Vinorelbine should be used with caution in patients with any pre-existing liver disease, kidney disease, lung disease, breathing trouble or any allergy. Because it may cause bleeding be careful when brushing or flossing teeth. Avoid contact with people that may have colds or flu or recently received the oral polio vaccine. Vinorelbine must be handled carefully because it can irritate the skin. Vinorlbine should be avoided if possible during pregnancy or lactation. A reliable form of contraception is recommended for use during therapy with this medication.